NASDAQ:SLS • US81642T2096
Past quarterly earnings results for SELLAS LIFE SCIENCES GROUP I (SLS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.06 | -0.07 | 9.99% | 40.00% | - | - | ||
| Q2 2025 | -0.07 | -0.08 | 15.82% | 46.15% | - | - | ||
| Q1 2025 | -0.07 | -0.11 | 33.99% | 66.67% | - | - | ||
| Q4 2024 | -0.08 | -0.11 | 26.20% | 68.00% | - | - | ||
| Q3 2024 | -0.10 | -0.13 | 23.84% | 69.70% | - | - | ||
| Q2 2024 | -0.13 | -0.17 | 21.99% | 58.06% | - | - | ||
| Q1 2024 | -0.21 | -0.16 | -29.95% | 55.32% | - | - | ||
| Q4 2023 | -0.25 | 0.00 | -8,900.90% | 41.86% | 13.13M | -100.00% | - | |
| Q3 2023 | -0.33 | 0.03 | -1,189.11% | 2.94% | 8.753M | -100.00% | - | |
| Q2 2023 | -0.31 | -0.36 | 13.54% | 24.39% | 3.283M | -100.00% | - | |
| Q1 2023 | -0.47 | -0.29 | -59.55% | 55.24% | - | -100.00% | ||
| Q4 2022 | -0.43 | -0.32 | -33.04% | -2.38% | - | - | ||
| Q3 2022 | -0.34 | -0.39 | 12.94% | 24.44% | - | - | ||
| Q2 2022 | -0.41 | -0.35 | -15.98% | -36.67% | - | -100.00% | ||
| Q1 2022 | -1.05 | -0.38 | -173.58% | -556.25% | 1M | - | -82.46% | |
| Q4 2021 | -0.42 | -0.41 | -1.42% | -50.00% | - | -100.00% | ||
| Q3 2021 | -0.45 | -0.38 | -18.29% | 15.09% | - | - | ||
| Q2 2021 | -0.30 | -0.39 | 23.84% | 54.55% | 1.9M | - | - | |
| Q1 2021 | -0.16 | -0.27 | 41.33% | 78.59% | 5.7M | - | - | |
| Q4 2020 | -0.28 | -0.28 | -0.81% | - | 1.9M | - | - | |
| Q3 2020 | -0.53 | -0.31 | -72.05% | - | - | - | ||
| Q2 2020 | -0.66 | -0.65 | -2.10% | - | - | - | ||
| Q1 2020 | -0.75 | - | - | - | - |
Notes
SELLAS LIFE SCIENCES GROUP I (SLS) last reported earnings on 11/12/2025.
SELLAS LIFE SCIENCES GROUP I (SLS) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, SELLAS LIFE SCIENCES GROUP I (SLS) has beaten EPS estimates in 4 out of 4 releases.